PET for drug development and evaluation
PET for drug development and evaluation
复制标题
PET 用于药物开发和评价
DOI：
10.1007/978-94-011-0429-6
复制
发表时间：
1995
影响因子：
6.1
通讯作者：
D. Comar
中科院分区：
文献类型：
--
作者：
D. Comar
第一部分：导言。1.药物开发和正电子发射断层扫描B。坎贝尔。2.正电子发射断层扫描：药理学研究的基本原理和潜在兴趣B。马佐耶3. PET是药物评价的工具吗？B。Langstrom，et al. Part 2：Psychiatry. 4. PET在神经精神药物开发中的应用法尔德5.放射性配体的处置和代谢-早期药物开发的关键信息。Halldin等人6.一种新型抗精神病药物的早期临床开发中的PET研究锡岑湖法尔德7. PET在开发多巴胺D1拮抗剂作为新的潜在抗精神病药物中的应用C. Foged，et al. 8. 5-HT2受体是抗精神病药物作用的靶点吗？患者和健康受试者多巴胺（D2）和5-羟色胺（5-HT 2）受体占用的PET研究。Nyberg等人9.用于PET-[11 C] WAY-100635研究中枢5-HT 1a受体的放射性配体的临床前开发Pike等人10.唑吡坦对omega（苯二氮卓）调节位点亚型的体内和体外选择性比较J. Benavides，et al. 11.阻断毒蕈碱受体对脑葡萄糖消耗的影响是否与正常志愿者阿尔茨海默病的皮质和皮质下代谢模式相似？J. Blin，et al. Part three：Neurology. 12. PET评价缺血性中风和阿尔茨海默病的药物治疗D.海斯13.急性缺血性卒中脑灌注和氧代谢的PET成像：对管理和治疗的意义男爵14.药代动力学：MAO抑制剂和D2拮抗剂的动力学建模。Lammertsma，C.J. Bench. 15.药物治疗下的脑激活P. Grasby，K.J. Friston。16. 17.帕金森氏病的发病机制和治疗方法COMT抑制：托卡朋和6-（18 F）-氟-L-多巴（FDOPA）PET结果的药理学K.乔加18.赖磺脲与多巴胺能受体B的相互作用。Maziere，A.安东尼尼19.赖磺脲和[C-11]-雷氯必利在D2受体位点K.L.的相互作用莱恩斯第四部分：心脏病学。20.心脏病药物设计：制药工业的观点。格拉德尼克21.心肌受体及其与心血管药物的相互作用。Syrota，P. Merlet. 22.心血管疾病的病理生理背景及其对诊断和治疗的影响卡米西23.通过11C-醋酸盐和PET L.M.评估强心剂对心肌耗氧量和效率的影响。Voipio-Pulkki等人24.在药物开发中整合新技术和经典技术。PET应用于丙酰-L-肉碱药代动力学研究A。Longo等人，第五部分：肿瘤学。25. EORTC新药开发办公室对抗癌药物H.R.临床（前）试验中PET的看法亨德里克斯，J.旺德斯。26.抗癌药物发现和开发的瓶颈：体内药代动力学和药效学问题以及PET的潜在作用。27.用于体内药代动力学研究的放射性标记抗癌药物
Part one: Introduction. 1. Drug development and positron emission tomography B. Campbell. 2. Positron emission tomography: Basic principles and potential interest for pharmacological studies B. Mazoyer. 3. Is PET a tool for drug evaluation? B. Langstrom, et al. Part two: Psychiatry. 4. PET in neuropsychiatric drug development L. Farde. 5. Radioligand disposition and metabolism - Key information in early drug development C. Halldin, et al. 6. PET studies in the early clinical development of a new antipsychotic J.M. Sitsen, L. Farde. 7. PET in the development of Dopamine D1 antagonists as new potential antipsychotic drugs C. Foged, et al. 8. Is the 5-HT2-receptor a target for antipsychotic drug action? PET studies on dopamine (D2) and serotonin (5-HT2) receptor occupancy in patients and healthy subjects S. Nyberg, et al. 9. Preclinical development of a radioligand for the study of central 5-HT1a receptors with PET-[11C]WAY-100635 V.W. Pike, et al. 10. Comparative in vivo and vitro selectivity of zolpidem for omega (Benzodiazepine) modulatory site subtypes J. Benavides, et al. 11. Do the effects of muscarinic receptor blockade on brain glucose consumption mimic the cortical and subcortical metabolic pattern of Alzheimer's disease in normal volunteers? J. Blin, et al. Part three: Neurology. 12. PET evaluation of drug treatment in ischemic stroke and Alzheimer's disease W.- D. Heiss. 13. PET imaging of cerebral perfusion and oxygen metabolism in acute ischemic stroke: Implications for management and therapy J.C. Baron. 14. Pharmacokinetics: Kinetic modelling of MAO inhibitors and D2 antagonists A. Lammertsma, C.J. Bench. 15. Brain activation under drug treatment P. Grasby, K.J. Friston. 16. Modifying the progression of Parkinson's disease P. Morrish, et al. 17. COMT inhibition: Pharmacology of tolcapone and 6- (18F)-Fluoro-L-Dopa (FDOPA) PET results K. Jorga. 18. Interaction of Lisuride with dopaminergic receptors B. Maziere, A. Antonini. 19. Lisuride and [C-11]-raclopride interaction at the D2 receptor site K.L. Leenders. Part four: Cardiology. 20. Drug design in cardiology: the pharmaceutical industry point of view R. Gradnik. 21. Myocardial receptors and their interaction with cardiovascular drugs A. Syrota, P. Merlet. 22. The pathophysiological background of cardiovascular diseases and its impact on diagnosis and treatment P.G. Camici. 23. Effect of cardiotonic drugs on myocardial oxygen consumption and efficiency as assessed by 11C-acetate and PET L.M. Voipio-Pulkki, et al. 24. Integration of new and classical techniques in drug development. PET application to Propionyl-L-carnitine pharmacokinetic study A. Longo, et al. Part five: Oncology. 25. The view of the EORTC new drug development office on PET in (pre)clinical trials of anticancer drugs H.R. Hendriks, J. Wanders. 26. Bottlenecks in anticancer drug discovery and development: In vivo pharmacokinetic and pharmacodynamic issues and the potential role of PET P. Workman. 27. Radiolabelled anticancer drugs for in vivo pharmacokinetic studies by